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Background. Human-Immunodeﬁciency-Virus- (HIV-) related Kaposi’s sarcoma (KS) has a high prevalence in Africa; however,
there is minimal published data on treatment and outcomes in this population. Objective and Design. This was a prospective study
of 50 patients, aiming to assess the impact of vincristine therapy on tumour response and survival and to assess palliative care
outcomes in patients with HIV-related KS. Methods. 50 consecutive patients were recruited during 2008. Vincristine therapy and
highly active antiretroviral therapy (HAART) were given. Tumour response, survival, and chemotherapy-related toxicities were
documented. Palliative care outcomes were assessed using the African Palliative Care Association (APCA) Palliative Outcome Scale
(POS). Results. The majority of patients were male, and the median age was 33 years. At baseline assessment, the median CD4
T-cell count was 263, and 50% patients had evidence of peripheral neuropathy. The overall response rate was 64% at 6 weeks,
and median progression-free survival was 30 weeks. Treatment was generally well tolerated, with peripheral neuropathy the main
dose-limiting toxicity. Conclusion. The combination of vincristine and HAART is feasible and eﬀective in a low resource setting,
although peripheral neuropathy is a dose-limiting factor. This patient group carries a high mortality and as such adequate access
to palliative care is crucial.
1.Introduction
Kaposi’s sarcoma (KS) is the most common human-immu-
nodeﬁciency virus- (HIV-) related malignancy, and the most
common malignancy in Malawi, explaining at 54% of cancer
diagnoses in males, and 27% in females from 1994–1998 [1].
Although widespread access to highly active antiretroviral
therapy(HAART)hasresultedinthereductioninprevalence
of KS in the developed world [2, 3], there is minimal data
regarding the impact of increased access to HAART in Sub-
SaharanAfrica.KSaccountedfor5–10%ofnewregistrations
for HAART in Malawi in 2005 and was associated with a
poorer outcome than for other patients on HAART [4].
Since antiretroviral therapy became available to patients in
Malawi from 2004, a ﬁxed dose combination of nevirapine,
stavudine, and lamivudine has been utilized as ﬁrst line ther-
apy for HIV.
Malawi is one of the poorest countries in Sub-Saharan
Africa and has an estimated HIV seroprevalence of approxi-
mately 12% [5]. Delivery of appropriate health care in these
circumstances presents a signiﬁcant challenge, with a lack
of human resource, unpredictable drug stocks, and poor
laboratory facilities. Infrastructure and expertise required
to administer and support combination chemotherapy are
lacking in most facilities. Until recently, HAART was avail-
able only to patients in industrialized countries; however, by
December 2005, over 800,000 patients had been commenced
on HAART in Africa [6]. Guidelines published by the
Government of Malawi Ministry of Health advocate the use
of single agent vincristine chemotherapy in association with2 AIDS Research and Treatment
HAART for the management of moderate-advanced KS [7].
This approach is utilized in other similar settings, although
there is a paucity of data relating to the objective response
rate of this treatment regimen.
Tiyanjane Clinic, at Queen Elizabeth Central Hospital
in Blantyre, Malawi, provides an outpatient palliative care
service and is a referral point for patients with moderate-
advanced cases of KS. Pharmacological therapy is given
alongside holistic care and support, where psychological,
social, and spiritual issues are discussed and explored. The
overall aim of the service is to improve the quality of life of
those with advanced disease.
Although palliative care services in Sub-Saharan Africa
are growing and improving, assessment of such services (as
with palliative care services world-wide) remains challenging
and outcomes largely unknown [8, 9]. The African Palliative
Care Association (APCA) Palliative Outcome Scale (POS), in
the appendix [10], is a simple and brief multidimensional
outcome measure intended to assist in measuring palliative
outcomes in routine clinical practice.
2.Objectives
This was a prospective study to assess the impact of vincris-
tine therapy on tumour response and survival and to
assess the feasibility of utilizing the APCA POS in patients
with HIV-related KS. Chemotherapy related toxicities were
documented.
3. Methods
Fifty patients being treated at the Tiyanjane Clinic were
recruited from April 2008 to December 2008. All patients
referred to the clinic that satisﬁed inclusion criteria were
oﬀered enrollment in the study and none declined. Informed
consent was obtained from all patients at the time of enroll-
ment, with thumbprints taken from those unable to write.
Ethics approval was obtained from the College of Medicine
Research Ethics Committee, College of Medicine, University
of Malawi.
Patients were eligible if they were aged 18–70, HIV
seropositive, had a clinical diagnosis of Kaposi’s sarcoma,
and fulﬁlled criteria for vincristine according to the Malawi
National Guidelines [7], those being as follows:
(i) presumed/conﬁrmed visceral disease,
(ii) cutaneous disease causing symptoms signiﬁcant
enough to impair function,
(iii) progressive disease despite use of ART.
Patients were excluded if they had signiﬁcant preexisting
myelosuppression (baseline hemoglobin levels <8g/dLand
a platelet count of <50/mm3), preexisting grade 3 or 4
peripheral neuropathy, clinical jaundice or known chronic
liver disease, pregnancy, or had received chemotherapy or
radiotherapy within last 6 weeks. Those considered to have
a life expectancy of less than 2 weeks and those with
active opportunistic infection (other than patients stable on
tuberculosis treatment) were also excluded.
Baseline assessment included detailed history, physical
examination,fullbloodscount,andCD4count.FurtherCD4
counts were not routinely performed given logistical and
funding constraints. Vincristine was given intravenously at a
dose of 2mg weekly for 6 doses, followed by 2mg fortnightly
for 6 doses, followed by 2mg monthly until progression or
unacceptable toxicity. At each consultation, holistic palliative
care was administered focusing on physical, psychosocial,
andspiritualissues.ThetreatingteamincludedaUK-trained
palliative care physician, an Australian medical oncologist,
and local nursing staﬀ trained in palliative care. All patients
had WHO stage IV HIV by deﬁnition [11].
3.1. Outcome Measures. The primary outcome measure was
tumour response. Patients were deﬁned as having complete
response (CR), partial response (PR), stable disease (SD),
or progressive disease (PD) as deﬁned by the AIDS Clini-
cal Trials Group (ACTG) response criteria [12], utilizing ser-
ial measurements and photographs of indicator lesions. Se-
condary endpoints were progression-free survival (PFS), de-
ﬁned as the time from study enrolment to either progres-
sion or death from any cause, chemotherapy-related toxici-
ty, and palliative care outcomes as measured using the APCA
POS tool. The APCA POS consists of a 10-point question-
nairecoveringphysical,psychological,andspiritualdomains.
Although this tool is able to be self-administered, those pa-
tients unable to read or write had the questions read to them
by a study nurse. Patients were given a choice of responding
to either the Chichewa or English version of the tool.
Chemotherapy-related toxicities were classiﬁed accord-
ing to the Common Terminology Criteria for Adverse Events
(Version 3.0, 2006).
3.2. Followup. Patients were reviewed every 3 doses of vin-
cristine, which equated to a review at 3 weeks, 6 weeks, 12
weeks, 18 weeks, and 30 weeks. Tumour response and chem-
otherapy toxicities were recorded at each review. An APCA
POS questionnaire was completed at each review.
3.3. Translational. The APCA POS tool, patient information
leaﬂet, and informed consent form were translated from En-
glish to Chichewa by clinical staﬀ ﬂuent in both Chichewa
andEnglish.Thestandardmethodologyoftranslation,back-
translation, and resolution of the diﬀerences between back
translation and the original was used.
3.4. Data Management and Analysis. Microsoft access was
used to record and analyze data. Each study proforma was
entered as a separate table linked in the database by the
unique identiﬁer assigned to each study subject. Personal
identiﬁers were maintained separately in one main ﬁle in a
password-protected computer ﬁle and used only as necessary
to match this information with the other databases. Only
the investigators of the study had access to this informa-
tion, which is securely stored and will be destroyed after
seven years. Descriptive statistics are used to describe most
results. Survival curves are presented and both intention-
to-treat (ITT) and per-protocol analyses of median PFS areAIDS Research and Treatment 3
Table 1: Baseline patient characteristics.
Characteristic Baseline
Age, (median (IQR)), years 33.5 (28–41)
Male (%) 40 (80.0)
KPS, median (IQR) 70 (50–80)
CD4 count, median (IQR) 263 (119–408)
Peripheral neuropathy (%)
Grade 1 (%)
Sensory (%)
25 (50)
18 (72%)
21 (84%)
HAART at baseline (%)
Median time on HAART prior
to recruitment (range)
37 (74%)
6.8 months (1–60)
presented. The Mann-Whitney U test was used to explore
associations between baseline CD4 counts and outcomes.
4. Results
Baseline demographic data are recorded in Table 1.M o s t
patients were male and aged between 28 and 41. Baseline
median Karnofsky performance status (KPS) [13]w a s7 0
(range 50–80), indicating that most patients were self-
caring however somewhat limited in their ability to perform
active work. 50% patients had a preexisting peripheral
neuropathy, which was predominantly sensory and grade 1.
Three patients had grade 2 neuropathy at baseline.
All patients had clinical evidence of cutaneous KS.
40 patients (80%) had oral cavity involvement, and 31
(62%) had clinical evidence of nodal involvement. 9 patients
(18%) had suspected visceral involvement, with 3 of these
conﬁrmed with either bronchoscopy or gastroscopy. The
majority (37, 74%) of patients had been commenced on
HAART prior to commencement of the study, for a median
of6.8months.Afurther8patientscommencedHAARTafter
study enrollment. All patients receiving HAART received
the standard regimen available in Malawi consisting of
nevirapine, stavudine, and lamivudine.
45 patients were evaluable at 3 weeks, 40 at 6 weeks,
36 at 12 weeks, 33 at 18 weeks, and 25 at 6 months. 16
(32%) patients died during the study period and 9 (18%)
defaulted despite intensive eﬀorts at followup (including
home visits and telephone calls). At 6 weeks, PR was seen
in 32 (64%) patients, and stable disease in 14%, for a clinical
beneﬁt rate of 78%. At 12 weeks, ongoing PR was seen in 26
(52%) patients and a further 4 had stable disease. The vast
majority of patients were taking oral HAART in addition to
receiving vincristine, and so the above response rates reﬂect
combination treatment with HAART and vincristine rather
than vincristine alone.
16 patients died during the study period. PFS data are
presentedin Figure 1.MedianPFSintheITTpopulationwas
30 weeks (i.e., just reached at the end of the study followup
period). Overall survival (OS) data are presented in Figure 2.
Median OS had not yet been reached at the end of the fol-
lowup period.
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Figure 1: Progression-free survival (intention-to-treat analysis).
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Figure 2: Overall survival.
There was no association between baseline CD4 count
and disease progression (median CD4 333 versus 256 in
progressors and nonprogressors, respectively, P = 0.13).
However, there was a trend towards a lower CD4 count in
those who died during study followup (149 versus 290 in
those dead and alive, respectively, P = 0.09).
Peripheral neuropathy was documented in 25 of 50
patients at baseline, and 20 of 33 evaluable patients at 18
weeks. Vincristine was ceased in 8 patients due to worsening
neuropathy (after a median of 6.5 doses). No signiﬁcant
myelosuppression occurred.
The baseline APCA POS assessment revealed moderate
levels of need in most domains (pain, other symptoms, level
of worry). Median pain scores and other symptom scores
showed a trend towards improvement over time (Figure 3).
Most responded positively to a question of life being worth-
while, and this did not alter during the course of the
study (Figure 4). Median scores for a question of feeling
at peace were low, as were scores regarding patients feel-
ing they had been given suﬃcient advice for the future.
These domains did not improve signiﬁcantly during the
study.
5. Discussion
This study is one of the few looking at patient outcomes in
HIV-associated KS, in the era of widespread antiretroviral4 AIDS Research and Treatment
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Figure 3: Changes in median APCA POS scores for pain and sym-
ptom control over time using the APCA POS. This graph depicts
the changes in median scores for questions 1 and 2 from baseline to
review number 5.
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Figure 4: Changes in median APCA POS score for psychosocial
domains. This graph depicts the changes in median scores for ques-
tions 3–7, from baseline to review number 5.
therapy in the developing world. We found that the combi-
nation of HAART and vincristine therapy is associated with
an impressive response rate, although there were no reports
of complete response in our study. Liposomal doxorubicin is
consideredthestandardofcareinthedevelopedworldonthe
basisoftwolargerandomizedclinicaltrials[14,15];however,
it is not only expensive, but can be associated with myelo-
suppression and gastrointestinal side eﬀects which would be
diﬃcult to manage currently in our setting. Northfelt et al.
reported 1 complete response and 60 partial responses out
of 133 patients who received liposomal doxorubicin, for an
overall response rate of 45.9% in their study [14]. Median
time to response was39 days. The highlyfavourableresponse
rate in our series is likely explained by a combination eﬀect
of vincristine, along with immune reconstitution associated
with HAART.
The diﬃculties in distinguishing the antitumour eﬀects
of HAART from the eﬀects of chemotherapy have been
previously described [16]. The FDA has previously suggested
that patients should receive an extended period of HAART
prior to being considered for chemotherapy. The Malawian
guidelines, for the use of vincristine described above, are
consistent with this suggestion. In our study, 74% patients
were receiving HAART for a median of 6.8 months prior
to commencing vincristine, which was consistent with these
guidelines.
There are few studies looking at the use of chemotherapy
for HIV-associated KS in Sub-Saharan Africa. Olweny et al.
[17] report on a randomized study of 495 patients in Zim-
babwecomparingtwochemotherapyregimens,radiotherapy
and best supportive care. No complete responses were seen,
howeversingleagentetoposidewasassociatedwithimproved
quality of life, and a partial response rate of 31%. Combina-
tion chemotherapy (actinomycin-D, bleomycin, vincristine)
was associated with a response rate of 49%, however with
considerable toxicity (alopecia, mucositis, nausea/vomiting).
No patient on this study received HAART. Bihl et al. report
on a small South African study of 33 patients, randomized to
HAART alone or HAART in combination with combination
chemotherapy (doxorubicin, bleomycin, vincristine) [18].
Both arms produced a profound decline in KSHV viraemia
and improved CD4 counts. 16 patients received HAART and
chemotherapy, with 7 (44%) achieving a complete response
and 7 (44%) achieving partial response when measured at
11 months, however the authors acknowledge considerable
toxicity of this regimen.
In our study, the combination of vincristine and HAART
was generally well tolerated, although peripheral neuropathy
was a dose-limiting factor in some patients. We found a
baseline peripheral neuropathy rate of 50%. The prevalence
ofHIV-relatedperipheralneuropathyvariesindiﬀerentpub-
lished series from 9–63%. References [19–24], with higher
rates seen in those with more advanced immunosuppression
andthoseonHAART.Asimilarlyhighincidenceofneuropa-
thy was reported in a large cross-sectional Ethiopian study,
with the majority of cases found in those receiving HAART
[24].Likelycontributingfactorsinourserieswerestavudine-
containing HAART, prior tuberculosis treatment, and HIV
neuropathy. Peripheral neuropathy is a particular concern in
this patient population, causing signiﬁcant morbidity with
a limited choice of agents available for symptom manage-
ment.
16 patients died during the six-month study period,
including 6 early deaths that occurred within 6 weeks of re-
cruitment. The median PFS in the ITT analysis was 30 weeks
in our study, which is comparable with survival data report-
ed by Olweny et al. [17]. Additional analysis presuming
all defaulted patients who had died revealed a medianAIDS Research and Treatment 5
progression-free survival of 24.5 weeks. This emphasizes the
need for taking a holistic approach to patient management,
aiming to improve quality of life for those in whom life ex-
pectancy is limited. Cause of death was diﬃcult to ascertain
in most cases given the majority of patients died at home.
There was a trend towards a lower baseline CD4 count in
those who died during the study. Given no clear association
between lower baseline CD4 counts and KS progression, it
is possible that opportunistic infections may have contribut-
ed to deaths more than progressive KS during the study
period. Immune reconstitution inﬂammatory syndrome
(IRIS) is well described in KS [25] and is another potential
causefordeterioration inpatients withKSreceivingHAART.
It is of interest that the baseline CD4 count of 263 in our
study is somewhat higher than previously published. In
similar cohorts [17, 26], further study regarding the causes
of death in this group would be of interest.
In this study we rigorously attempted to contact patients
who failed to attend appointments ﬁrstly by telephone and
thenbyhomevisits.ItiscommonculturalpracticeinMalawi
to travel home to the family village as people near the end
of their life. This may have contributed to at least 3 pa-
tients being lost to follow up. 3 others were known to have
potentially life threatening conditions at the point of last
contact—one with a large cerebrovascular accident, one with
Stevens-Johnsons-syndrome thought secondary to HAART,
and one with proven gastrointestinal KS. A prior study
of patients on an antiretroviral programme in Lilongwe,
Malawi, found that of those lost to follow-up, 41% were later
found to have died [27]. It is likely that death was the cause
of several defaults in this study.
Due to lack of access to prompt histopathological
services, the diagnosis of KS in this study was made clinically
by two experienced physicians. Histological conﬁrmation
would have been ideal if feasible.
The APCA POS tool has been validated for use in an
African setting. We utilized it in this survey in an attempt to
measure palliative care outcomes. Whilst some trends could
be elucidated, we observed that the patients and families
in our study found the questionnaire diﬃcult to complete.
They struggled to use numerical rating scales to express
the magnitude of a subjective experience, even with the
assistance of a research nurse. More reﬁnement in such
assessment tools is needed before they can be used reliably
in our population group.
6. Conclusion
HIV-related KS is a common problem in Malawi. The com-
bination of vincristine and ART is a feasible option for the
treatment of patients with moderate-advanced disease in a
low resource setting and is associated with good response
rates; however, peripheral neuropathy is a dose-limiting fac-
tor. Given the poor prognosis in this patient group, adequate
palliative care remains of upmost importance. Optimal utili-
zation of a palliative care assessment tool remains a challenge
in our setting.
Appendix
A. AfricanPalliativeOutcome Scale(APOS).
Study number Staﬀ name
Date POS no 1st 2nd 3rd 4th 5th
6th
Ask the patient
Q1. Please rate your pain (from 0 = no pain to 5
worst/overwhelming pain) during the last 3 days
Q2. Have any other symptoms (e.g., nausea, coughing or
constipation) been aﬀecting how you feel in the last 3 days?
Q3. Have you been feeling worried about your illness the
past 3 days?
Q4. Over the past 3 days, have you been able to share how
you are feeling with your family or friends?
Q5. Over the past 3 days have you felt that life was
worthwhile?
Q6. Over the past 3 days, have you felt at peace?
Q7. Have you had enough help and advice for your family
to plan for the future?
Ask the family carer
Q8. How much information have you and your family been
given?
Q9. How conﬁdent does the family feel caring for ?
Q10. Has the family been feeling worried about the patient
over the last 3 days?
Possible responses
A1. 0 (no pain)–5 (worst/overwhelming pain)
0  1  2  3  4  5 
A2. 0 (not at all)–5 (overwhelmingly)
0  1  2  3  4  5 
A3. 0 (not at all)–5 (overwhelming worry)
0  1  2  3  4  5 
A4. 0 (not at all)–5 (yes, I’ve talked freely)
0  1  2  3  4  5 
A5. 0 (no, not at all)–5 (yes, all the time)
0  1  2  3  4  5 
A6. 0 (no, not at all)–5 (Yes, all the time)
0  1  2  3  4  5 
A7. 0 (not at all)–5 (as much as wanted)
0  1  2  3  4  5 
A8. 0 (none)–5 (as much as wanted)
N/A 
0  1  2  3  4  5 
A9. 0 (not at all)–5 (very conﬁdent)
N/A 
0  1  2  3  4  5 
A10. 0 (not at all)–5 (severe worry)
N/A 
0  1  2  3  4  5 6 AIDS Research and Treatment
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